The active substances in herring roe that produce healing effects in mild to moderate psoriasis

Background:

This innovation project is part of Arctic Bioscience’s extensive research and development work and is being carried out in collaboration with Nofima and Møreforsking. Arctic Biosciences has a drug candidate (called HRO350) based on herring roe that has shown promising clinical efficacy for mild-to-moderate psoriasis. 

In this project, we will take a closer look at how it affects cells. The aim is to develop a new treatment option for patients with mild-to-moderate psoriasis.

Objective

The aim of this project is to identify which active substances in herring roe produce healing effects in mild to moderate psoriasis. 

This is what we are doing

Arctic Bioscience has extensive experience in respect of lipid chemistry and its own laboratory in Ørsta where chemists are working on product development, while Nofima and Møreforsking have expertise in biochemistry and cell biology. 

The partners will work together to use cell models for studying the molecular mechanisms of substances in herring roe. 

Under this project the partners will develop new advanced cell models and methods. Nofima will develop a cell model system for skin using co-cultures. 

By growing different types of cells that are found in the skin,  we will  achieve a model mimicking the biological processes in the skin in vivo.